etidronate has been researched along with Prostatic Neoplasms in 93 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To calculate radiation doses of rhenium-186 ((186)Re) etidronate in painful bone metastases using quantitative bone single-photon emission computed tomography (SPECT) and to determine the threshold dose for predicting pain relief." | 9.09 | Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. ( Betman, L; Frenkel, A; Front, D; Iosilevski, G; Israel, O; Keidar, Z; Kolodny, GM; Kuten, A; Rubinov, R; Yarnitsky, D, 2000) |
| "Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain." | 9.09 | [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. ( Csernay, L; Láng, J; Pajor, L; Pávics, L; Róka, R; Séra, T; Thurzó, L, 2000) |
| "Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts)." | 9.09 | [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. ( Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R, 2000) |
| "Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases." | 9.08 | [Pain therapy with rhenium-186 HEDP in multiple bone metastases]. ( Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P, 1996) |
| "To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (89Sr) in patients with painful osteoblastic metastases primarily from prostate and breast cancer." | 8.79 | Strontium 89 therapy for the palliation of pain due to osseous metastases. ( Baxter, KG; Preston, DF; Robinson, RG; Schiefelbein, M, 1995) |
| "The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with (186)Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer." | 7.75 | Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. ( Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009) |
| "Twelve consecutive men with disseminated prostate carcinoma were evaluated at 0, 6, and 12 months after treatment with a long acting gonadotropin-releasing hormone agonist (goserelin acetate) and an androgen antagonist (flutamide)." | 7.70 | The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. ( Bryant, C; Campbell, J; Diamond, T; Lynch, W, 1998) |
| "A potential limitation of rhenium-186-1,1-hydroxyethylidene diphosphonate (186Re-HEDP) therapy in patients with painful bone metastases is thrombocytopenia." | 7.69 | Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. ( Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994) |
| "A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38." | 5.31 | Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy. ( Franke, WG; Hliscs, R; Kropp, J; Liepe, K, 2000) |
| "Rhenium-188-HEDP ((188)Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain." | 5.10 | Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. ( Kotzerke, J; Kropp, J; Liepe, K; Runge, R, 2003) |
| "To calculate radiation doses of rhenium-186 ((186)Re) etidronate in painful bone metastases using quantitative bone single-photon emission computed tomography (SPECT) and to determine the threshold dose for predicting pain relief." | 5.09 | Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. ( Betman, L; Frenkel, A; Front, D; Iosilevski, G; Israel, O; Keidar, Z; Kolodny, GM; Kuten, A; Rubinov, R; Yarnitsky, D, 2000) |
| "Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain." | 5.09 | [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. ( Csernay, L; Láng, J; Pajor, L; Pávics, L; Róka, R; Séra, T; Thurzó, L, 2000) |
| "Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts)." | 5.09 | [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. ( Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R, 2000) |
| "The aim of this study was to evaluate the efficacy of rhenium-186 hydroxyethyledine diphosphonate (Re-186 HEDP) for pain relief in patients with disseminated bone metastases primarily from prostate or breast cancer." | 5.08 | Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results. ( Biersack, HJ; Dierke-Dzierzon, C; Müller, SC; Palmedo, H; Schoeneich, G, 1997) |
| "Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases." | 5.08 | [Pain therapy with rhenium-186 HEDP in multiple bone metastases]. ( Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P, 1996) |
| "To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (89Sr) in patients with painful osteoblastic metastases primarily from prostate and breast cancer." | 4.79 | Strontium 89 therapy for the palliation of pain due to osseous metastases. ( Baxter, KG; Preston, DF; Robinson, RG; Schiefelbein, M, 1995) |
| "The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with (186)Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer." | 3.75 | Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. ( Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009) |
| "Twelve consecutive men with disseminated prostate carcinoma were evaluated at 0, 6, and 12 months after treatment with a long acting gonadotropin-releasing hormone agonist (goserelin acetate) and an androgen antagonist (flutamide)." | 3.70 | The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. ( Bryant, C; Campbell, J; Diamond, T; Lynch, W, 1998) |
| "A potential limitation of rhenium-186-1,1-hydroxyethylidene diphosphonate (186Re-HEDP) therapy in patients with painful bone metastases is thrombocytopenia." | 3.69 | Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. ( Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994) |
| "Prostate or breast cancer patients with painful bone metastases receiving (188)Re-HEDP as a routine clinical procedure were eligible for evaluation." | 2.82 | Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. ( Bloemendal, HJ; de Klerk, JM; Hendrikse, NH; Kooistra, A; Lange, R; Overbeek, F; Pasker-de Jong, PC; Rodenburg, CJ; Ter Heine, R; van den Berk, AM, 2016) |
| "Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss." | 2.76 | Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. ( Izumi, K; Kitagawa, Y; Koh, E; Mizokami, A; Namiki, M; Narimoto, K; Sugimoto, K, 2011) |
| "A dose escalation schedule was designed consisting of four dose levels with a standard dosage of docetaxel (75 mg/m(2) 3-weekly)." | 2.76 | A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). ( Bloemendal, HJ; de Haas, MJ; de Klerk, JM; O'Sullivan, JM; van Bezooijen, BP; van Dodewaard-de Jong, JM; Wilson, RH, 2011) |
| " The primary end-point was to establish the maximum tolerable dose (MTD) of capecitabine when combined with (188)Re-HEDP." | 2.74 | (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. ( Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009) |
| "In total, 79 patients (18 with breast cancer and 61 with prostate cancer) were treated (31 patients with 188Re-HEDP, 15 patients each with 186Re-HEDP and 153Sm-EDTMP, and 18 patients with 89Sr)." | 2.73 | A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. ( Kotzerke, J; Liepe, K, 2007) |
| "Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture." | 2.73 | Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. ( Ishizaka, K; Kanbe, N; Kitahara, S; Kobayashi, S; Machida, T; Yoshida, K, 2007) |
| "Thirteen prostate cancer patients with skeletal involvement were treated with 2,700-3,459 MBq (mean dose, 3,120 MBq) (188)Re-HEDP." | 2.71 | Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. ( Franke, WG; Hliscs, R; Knapp, FF; Kropp, J; Liepe, K; Runge, R, 2003) |
| " Of the six patients treated at the highest dosage schedules (three at 1510 MBq/m2 and three at 1665 MBq/m2), three showed a posttherapy decline in prostate-specific antigen of 50% or more." | 2.69 | Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. ( Curley, T; Daghighian, F; Goldsmith, SJ; Graham, MC; Larson, SM; Liu, GB; Scher, HI; Yeh, SD, 1999) |
| "Twenty-nine prostatic cancer patients with multiple painful bone metastases were included in the study." | 2.69 | Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP? ( de Klerk, JM; Huiskes, AW; van Dijk, A; van Het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1999) |
| "It is concluded that in prostate cancer patients, the maximum tolerated dose of 188Re-HEDP is 3." | 2.69 | Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. ( Bender, H; Biersack, HJ; Grünwald, F; Guhlke, S; Knapp, FF; Palmedo, H; Risse, J; Sartor, J; Schoeneich, G, 2000) |
| "Twenty-eight patients (12 men with prostate cancer, 16 women with breast cancer) were included in a phase II trial to evaluate the efficacy of 186Re-hydroxyethylidene diphosphonate (HEDP) on pain from bone metastasis and the toxicity of this agent." | 2.69 | Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. ( Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P, 2000) |
| "Treatment with zoledronic acid probably neither reduces nor increases the proportion of participants with pain response when compared to no treatment/placebo (risk ratio (RR) 1." | 2.66 | Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. ( Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM, 2020) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| " Their use as single agents with dose escalations, in combination with biphosphonates or chemotherapy is well known in the peer-reviewed literature; however, little is known about the combination between different agents." | 1.39 | Radionuclide therapy of painful bone metastases--a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness. ( Gouliamos, A; Limouris, GS; Sideras, PA; Stavraka, A, 2013) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "33 patients (30 prostate carcinoma, 3 breast carcinoma) were treated with 150 MBq 89SrCl2 (9 patients), 1295 MBq 186Re-HEDP (12 patients) or 37 MBq/kg 153Sm-EDTMP (12 patients)." | 1.35 | Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP. ( de Klerk, JM; Hoekstra, A; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009) |
| "A total of 69 men with prostate cancer were assigned to receive either oral risedronate or none during ADT (hormone naïve)." | 1.35 | [Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy]. ( Bab, S; Hayakawa, K; Hyodo, T; Iwamura, M; Kimura, M; Matsumoto, K; Okazaki, M; Satoh, T; Soh, S; Tabata, K; Tsuboi, T; Yokoyama, E, 2008) |
| "Patients with skeletal metastases from hormone-refractory prostate cancer have shown variable responses to high-activity therapy with (186)Re-HEDP and peripheral stem cell support." | 1.33 | The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer. ( Binnie, D; Dearnaley, D; Divoli, A; Flux, G; McCready, VR, 2005) |
| "A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38." | 1.31 | Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy. ( Franke, WG; Hliscs, R; Kropp, J; Liepe, K, 2000) |
| "We report on two prostatic cancer patients with metastatic bone cancer." | 1.29 | Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment. ( Blijham, GH; de Klerk, JM; Krouwer, HG; van Die, J; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996) |
| "Although the function of normal bone marrow is affected by metastases in patients with metastatic bone disease, the MIRD model can be used to relate toxicity to the bone marrow absorbed dose after a therapeutic dosage of 186Re-HEDP." | 1.29 | Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. ( Blijham, GH; de Klerk, JM; Hoekstra, A; Rutgers, DH; van Dieren, EB; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996) |
| " Half-life times of 186Re in three blood fractions (whole blood, plasma and plasma water) were 40." | 1.28 | Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. ( de Klerk, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1992) |
| "A 77-year-old man with prostate cancer was serially evaluated for bone metastases using Tc-99m methylene disphosphonate (Tc-99m MDP) both on and off treatment with etidronate disodium (EHDP)." | 1.27 | False-negative bone imaging due to etidronate disodium therapy. ( Collier, BD; Ewey, D; Hellman, RS; Isitman, AT; Krasnow, AZ, 1988) |
| "This osteolysis was evaluated by measuring the increased area of bone resorption by its reduced opacity to X-ray, and histology." | 1.27 | Establishment of a model to evaluate inhibition of bone resorption induced by human prostate cancer cells in nude mice. ( Harada, M; Kanoh, S; Koiso, K; Nemoto, R, 1988) |
| "These appearances are frequently seen in renal osteodystrophy but are uncommon in malignant disease." | 1.26 | Absent kidney sign associated with symmetrical and uniformly increased uptake of radiopharmaceutical by the skeleton. ( Boyle, IT; Fogelman, I; Greig, WR; McKillop, JH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (13.98) | 18.7374 |
| 1990's | 28 (30.11) | 18.2507 |
| 2000's | 35 (37.63) | 29.6817 |
| 2010's | 15 (16.13) | 24.3611 |
| 2020's | 2 (2.15) | 2.80 |
| Authors | Studies |
|---|---|
| Alshehri, AHD | 1 |
| Osman, SOS | 1 |
| Prise, KM | 1 |
| Campfield, C | 1 |
| Turner, PG | 1 |
| Jain, SFP | 1 |
| O'Sullivan, JM | 7 |
| Cole, AJ | 1 |
| Jakob, T | 1 |
| Tesfamariam, YM | 1 |
| Macherey, S | 1 |
| Kuhr, K | 1 |
| Adams, A | 1 |
| Monsef, I | 1 |
| Heidenreich, A | 1 |
| Skoetz, N | 1 |
| Denis-Bacelar, AM | 1 |
| Chittenden, SJ | 2 |
| McCready, VR | 5 |
| Divoli, A | 3 |
| Dearnaley, DP | 5 |
| Johnson, B | 2 |
| Flux, GD | 3 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| ter Heine, R | 3 |
| Lange, R | 3 |
| Breukels, OB | 1 |
| Bloemendal, HJ | 4 |
| Rummenie, RG | 1 |
| Wakker, AM | 1 |
| de Graaf, H | 1 |
| Beekman, FJ | 1 |
| van der Westerlaken, MM | 1 |
| Malingré, MM | 1 |
| Wielders, JP | 1 |
| van den Berg, L | 1 |
| Hendrikse, NH | 3 |
| de Klerk, JM | 13 |
| Overbeek, F | 1 |
| Pasker-de Jong, PC | 1 |
| van den Berk, AM | 1 |
| Rodenburg, CJ | 1 |
| Kooistra, A | 1 |
| van Wieringen, WN | 1 |
| Tromp, AM | 1 |
| Paap, M | 1 |
| Geldof, AA | 3 |
| Lam, MG | 2 |
| Hoekstra, A | 2 |
| van Rijk, PP | 10 |
| Zonnenberg, BA | 10 |
| Bosma, TB | 1 |
| Izumi, K | 2 |
| Mizokami, A | 2 |
| Sugimoto, K | 2 |
| Narimoto, K | 2 |
| Miwa, S | 1 |
| Maeda, Y | 1 |
| Kadono, Y | 1 |
| Takashima, M | 1 |
| Koh, E | 2 |
| Namiki, M | 2 |
| Kearns, AE | 1 |
| Northfelt, DW | 1 |
| Dueck, AC | 1 |
| Atherton, PJ | 1 |
| Dakhil, SR | 1 |
| Rowland, KM | 1 |
| Fuloria, J | 1 |
| Flynn, PJ | 1 |
| Dentchev, T | 1 |
| Loprinzi, CL | 1 |
| Liepe, K | 7 |
| Geidel, HH | 1 |
| Bergmann, R | 1 |
| Haase, M | 1 |
| Runge, R | 5 |
| Kotzerke, J | 4 |
| Zafeirakis, A | 2 |
| Zissimopoulos, A | 2 |
| Baziotis, N | 2 |
| Limouris, GS | 3 |
| Taxel, P | 1 |
| Dowsett, R | 1 |
| Richter, L | 1 |
| Fall, P | 1 |
| Klepinger, A | 1 |
| Albertsen, P | 1 |
| Kitagawa, Y | 1 |
| van Dodewaard-de Jong, JM | 1 |
| van Bezooijen, BP | 1 |
| de Haas, MJ | 1 |
| Wilson, RH | 1 |
| Biersack, HJ | 5 |
| Palmedo, H | 5 |
| Andris, A | 1 |
| Rogenhofer, S | 1 |
| Knapp, FF | 4 |
| Guhlke, S | 3 |
| Ezziddin, S | 2 |
| Bucerius, J | 1 |
| von Mallek, D | 1 |
| Meulenbeld, HJ | 1 |
| van Werkhoven, ED | 1 |
| Coenen, JL | 1 |
| Creemers, GJ | 1 |
| Loosveld, OJ | 1 |
| de Jong, PC | 1 |
| Ten Tije, AJ | 1 |
| Fosså, SD | 1 |
| Polee, M | 1 |
| Gerritsen, W | 1 |
| Dalesio, O | 1 |
| de Wit, R | 1 |
| Orsini, F | 1 |
| Guidoccio, F | 1 |
| Mazzarri, S | 1 |
| Mariani, G | 1 |
| Sideras, PA | 1 |
| Stavraka, A | 1 |
| Gouliamos, A | 1 |
| Choo, R | 1 |
| Lukka, H | 1 |
| Cheung, P | 1 |
| Corbett, T | 1 |
| Briones-Urbina, R | 1 |
| Vieth, R | 1 |
| Ehrlich, L | 1 |
| Kiss, A | 1 |
| Danjoux, C | 1 |
| Han, SH | 4 |
| Tan, S | 1 |
| van het Schip, AD | 8 |
| Derksen, BH | 1 |
| van Dijk, A | 8 |
| Kruitwagen, CL | 1 |
| Blijham, GH | 6 |
| Buffa, FM | 3 |
| Guy, MJ | 1 |
| Hliscs, R | 3 |
| Kropp, J | 4 |
| Franke, WG | 3 |
| Manka-Waluch, A | 1 |
| Albers, P | 1 |
| Schmidt-Wolf, IG | 1 |
| Reinhardt, M | 1 |
| Joe, A | 1 |
| Roedel, R | 1 |
| Fimmers, R | 1 |
| Hershman, D | 1 |
| Narayanan, R | 1 |
| Binnie, D | 1 |
| Dearnaley, D | 1 |
| Flux, G | 3 |
| Norman, AR | 2 |
| Coffey, J | 1 |
| Cook, G | 2 |
| Treleaven, J | 2 |
| Horwich, A | 2 |
| Huddart, RA | 2 |
| Parker, CC | 1 |
| van der Poel, HG | 1 |
| Antonini, N | 1 |
| Hoefnagel, CA | 1 |
| Horenblas, S | 1 |
| Valdes Olmos, RA | 1 |
| Minutoli, F | 1 |
| Herberg, A | 1 |
| Spadaro, P | 1 |
| Restifo Pecorella, G | 1 |
| Baldari, S | 2 |
| Aricò, D | 1 |
| Altavilla, G | 1 |
| Bloch, G | 1 |
| Chittenden, S | 2 |
| Malaroda, A | 1 |
| Ishizaka, K | 1 |
| Machida, T | 1 |
| Kobayashi, S | 1 |
| Kanbe, N | 1 |
| Kitahara, S | 1 |
| Yoshida, K | 1 |
| Kimura, M | 1 |
| Satoh, T | 1 |
| Okazaki, M | 1 |
| Tabata, K | 1 |
| Tsuboi, T | 1 |
| Hyodo, T | 1 |
| Yokoyama, E | 1 |
| Matsumoto, K | 1 |
| Soh, S | 1 |
| Iwamura, M | 1 |
| Hayakawa, K | 1 |
| Bab, S | 1 |
| Koutsikos, J | 1 |
| Leondi, A | 1 |
| Boedecker, RA | 1 |
| Blake, DG | 1 |
| Sty, JR | 1 |
| Riegert, MR | 1 |
| Chisholm, GD | 1 |
| Stone, AR | 1 |
| Beynon, LL | 1 |
| Merrick, MV | 1 |
| Quirijnen, JM | 2 |
| Robinson, RG | 1 |
| Preston, DF | 1 |
| Schiefelbein, M | 1 |
| Baxter, KG | 1 |
| Stokkel, MP | 1 |
| van Dieren, EB | 1 |
| Rutgers, DH | 1 |
| Silberstein, EB | 1 |
| Bender, H | 2 |
| Schomburg, A | 1 |
| Grünwald, F | 2 |
| Schöneich, G | 1 |
| Zamorra, P | 1 |
| Reichmann, K | 1 |
| Dierke-Dzierzon, C | 2 |
| Mallmann, P | 1 |
| Krouwer, HG | 1 |
| van Die, J | 1 |
| ten Kroode, HF | 1 |
| van den Tillaar, PL | 1 |
| Newling, DW | 2 |
| Teule, GJ | 2 |
| van Aswegen, A | 1 |
| Roodt, A | 1 |
| Marais, J | 1 |
| Botha, JM | 1 |
| Naudé, H | 1 |
| Lötter, MG | 1 |
| Goedhals, L | 1 |
| Doman, MJ | 1 |
| Otto, AC | 1 |
| Adami, S | 1 |
| Schoeneich, G | 2 |
| Müller, SC | 1 |
| Holle, LH | 1 |
| Humke, U | 1 |
| Trampert, L | 1 |
| Ziegler, M | 1 |
| Kirsch, CM | 1 |
| Oberhausen, E | 1 |
| Maxon, HR | 4 |
| Schroder, LE | 4 |
| Washburn, LC | 1 |
| Thomas, SR | 4 |
| Samaratunga, RC | 2 |
| Biniakiewicz, D | 1 |
| Moulton, JS | 3 |
| Cummings, D | 1 |
| Ehrhardt, GJ | 2 |
| Morris, V | 1 |
| Lerch, H | 1 |
| Diamond, T | 1 |
| Campbell, J | 1 |
| Bryant, C | 1 |
| Lynch, W | 1 |
| de Rooij, L | 1 |
| Versteegh, RT | 1 |
| Graham, MC | 1 |
| Scher, HI | 3 |
| Liu, GB | 1 |
| Yeh, SD | 1 |
| Curley, T | 2 |
| Daghighian, F | 1 |
| Goldsmith, SJ | 1 |
| Larson, SM | 1 |
| Huiskes, AW | 1 |
| De Winter, F | 1 |
| Brans, B | 1 |
| Van De Wiele, C | 1 |
| Dierckx, RA | 1 |
| Major, PP | 1 |
| Lipton, A | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| Giannakenas, C | 1 |
| Kalofonos, HP | 1 |
| Apostolopoulos, DJ | 1 |
| Zarakovitis, J | 1 |
| Kosmas, C | 1 |
| Vassilakos, PJ | 1 |
| Sartor, J | 1 |
| Risse, J | 1 |
| Sciuto, R | 1 |
| Tofani, A | 1 |
| Festa, A | 1 |
| Giannarelli, D | 1 |
| Pasqualoni, R | 1 |
| Maini, CL | 1 |
| Siberstein, EB | 1 |
| Róka, R | 1 |
| Séra, T | 1 |
| Pajor, L | 1 |
| Thurzó, L | 1 |
| Láng, J | 1 |
| Csernay, L | 1 |
| Pávics, L | 1 |
| Israel, O | 1 |
| Keidar, Z | 1 |
| Rubinov, R | 1 |
| Iosilevski, G | 1 |
| Frenkel, A | 1 |
| Kuten, A | 1 |
| Betman, L | 1 |
| Kolodny, GM | 1 |
| Yarnitsky, D | 1 |
| Front, D | 1 |
| Klutmann, S | 1 |
| Bohuslavizki, KH | 1 |
| Küçük, NO | 1 |
| Ibiş, E | 1 |
| Aras, G | 1 |
| Baltaci, S | 1 |
| Ozalp, G | 1 |
| Bedük, Y | 1 |
| Canakci, N | 1 |
| Soylu, A | 1 |
| Kolesnikov-Gauthier, H | 1 |
| Carpentier, P | 1 |
| Depreux, P | 1 |
| Vennin, P | 1 |
| Caty, A | 1 |
| Sulman, C | 1 |
| Koch, R | 1 |
| Piffanelli, A | 2 |
| Dafermou, A | 2 |
| Giganti, M | 2 |
| Colamussi, P | 2 |
| Pizzocaro, C | 1 |
| Bestagno, M | 2 |
| Cittanti, C | 1 |
| Guy, M | 1 |
| Pomeroy, K | 1 |
| Gadd, J | 1 |
| Al-Deen, A | 1 |
| Fogelman, I | 2 |
| Goll, C | 1 |
| McKillop, JH | 2 |
| Citrin, DL | 2 |
| Greig, WR | 2 |
| Potsaid, MS | 1 |
| Irwin, RJ | 1 |
| Castronovo, FP | 1 |
| Prout, GR | 1 |
| Harvey, WJ | 2 |
| Francis, MD | 2 |
| Tofe, AJ | 2 |
| Zamenhof, RG | 1 |
| Boyle, IT | 1 |
| Bessent, RG | 1 |
| McGinley, E | 1 |
| Gordon, D | 1 |
| Yeh, S | 1 |
| Tong, W | 1 |
| O'Moore, PV | 1 |
| Larson, S | 1 |
| Englaro, EE | 2 |
| Williams, CC | 3 |
| Hertzberg, VS | 2 |
| Deutsch, EA | 1 |
| Libson, KF | 1 |
| Samaratunga, R | 1 |
| Smith, H | 1 |
| Shevrin, DH | 1 |
| Gorny, KI | 1 |
| Rosol, TJ | 1 |
| Kukreja, SC | 1 |
| Nemoto, R | 2 |
| Sato, S | 1 |
| Nishijima, Y | 1 |
| Miyakawa, I | 1 |
| Koiso, K | 2 |
| Harada, M | 2 |
| Carey, PO | 1 |
| Lippert, MC | 1 |
| Smith, JA | 1 |
| Percival, RC | 1 |
| Urwin, GH | 1 |
| Harris, S | 1 |
| Yates, AJ | 1 |
| Williams, JL | 1 |
| Beneton, M | 1 |
| Kanis, JA | 1 |
| Krasnow, AZ | 1 |
| Collier, BD | 1 |
| Isitman, AT | 1 |
| Hellman, RS | 1 |
| Ewey, D | 1 |
| Kawamura, J | 1 |
| Tochigi, H | 1 |
| Yanagawa, M | 1 |
| Yoshida, O | 1 |
| Hida, S | 1 |
| Mori, O | 1 |
| Suzuki, N | 1 |
| Saito, K | 1 |
| Komatsu, Y | 1 |
| Hatayama, T | 1 |
| Kanoh, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate[NCT00019695] | Phase 2 | 0 participants | Interventional | 1999-03-31 | Terminated | ||
| Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study[NCT00181558] | Phase 2 | 44 participants | Interventional | 2001-12-31 | Completed | ||
| A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone[NCT00079001] | Phase 3 | 645 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates[NCT00104650] | Phase 2 | 111 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease[NCT00685646] | Phase 3 | 227 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Pred[NCT00554918] | Phase 2 | 300 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer[NCT00321620] | Phase 3 | 1,904 participants (Actual) | Interventional | 2006-04-01 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060] | Phase 3 | 63 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Terminated due to low accrual) | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study[NCT00043069] | Phase 3 | 71 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study[NCT03458559] | Phase 3 | 402 participants (Anticipated) | Interventional | 2018-05-16 | Active, not recruiting | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 37.9 |
| Placebo + Androgen Deprivation Therapy | 36.0 |
"Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment." (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 10.6 |
| Placebo + Androgen Deprivation Therapy | 9.2 |
Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 31.9 |
| Placebo + Androgen Deprivation Therapy | 28.8 |
Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 25 |
| Denosumab 180 mg Q12W | 32 |
| Denosumab 180 mg Q4W | 35 |
Occurrence of hypercalcemia at grade 3 or 4 according to CTCAE v3 criteria (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 0 |
| Denosumab 180 mg Q12W | 0 |
| Denosumab 180 mg Q4W | 0 |
Percent change from baseline to week 25 in Type I serum C-Telopeptide (CTX), calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -40.68 |
| Denosumab 180 mg Q12W | -76.74 |
| Denosumab 180 mg Q4W | -68.39 |
Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -32.91 |
| Denosumab 180 mg Q12W | -69.09 |
| Denosumab 180 mg Q4W | -41.68 |
Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Time from study day 1 to first Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Days (Median) |
|---|---|
| Bisphosphonate IV Q4W | 65 |
| Denosumab 180 mg Q12W | 9 |
| Denosumab 180 mg Q4W | 10 |
Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13. (NCT00104650)
Timeframe: 13 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 10 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 28 |
Urinary N-telopeptide (uNTX) corrected by creatinine < 50 nmol/mmol at week 25. (NCT00104650)
Timeframe: 25 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 13 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 23 |
Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.~This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events." (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Events (Number) |
|---|---|
| Zoledronic Acid | 584 |
| Denosumab | 494 |
Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Risedronate Arm | 11 |
| Placebo Arm | 13 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate Arm | 50 |
| Placebo Arm | 29 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate | 72.5 |
| Placebo | 71.5 |
"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks
| Intervention | nmol/mmol creatinine (Median) | |
|---|---|---|
| week 24 | baseline | |
| Placebo Arm | 12.62 | 10.12 |
| Risedronate Arm | 6.91 | 8.83 |
Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week
| Intervention | ng/mL (Median) | |
|---|---|---|
| 24 week | baseline | |
| Placebo Arm | 13.16 | 19.50 |
| Risedronate Arm | 9.5 | 20.95 |
Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week
| Intervention | ug/L (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 27.35 | 18.24 |
| Risedronate Arm | 11.88 | 20.08 |
"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week
| Intervention | nmol BCE/mmol creatinine (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 62.95 | 48.08 |
| Risedronate Arm | 20.63 | 41.33 |
6 reviews available for etidronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation | 2004 |
Strontium 89 therapy for the palliation of pain due to osseous metastases.
Topics: Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Drugs, Investigational; Etidronic Acid; Fem | 1995 |
Bisphosphonates in prostate carcinoma.
Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C | 1997 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances; | 1992 |
37 trials available for etidronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Cancer Pain; Comorbidity; Etidronic Acid; Female; Humans; Ma | 2016 |
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Eti | 2009 |
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Double-Blind | 2010 |
Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Epidemiologic | 2010 |
Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antineoplastic Age | 2011 |
A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
Topics: Aged; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Orchi | 2011 |
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Com | 2012 |
Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Density Cons | 2013 |
The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
Topics: Aged; Bone Neoplasms; Double-Blind Method; Etidronic Acid; Humans; Male; Organometallic Compounds; P | 2002 |
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Topics: Body Burden; Bone Marrow; Bone Neoplasms; Computer Simulation; Etidronic Acid; Humans; Injections, I | 2003 |
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Topics: Aged; Aged, 80 and over; Body Burden; Bone Marrow; Bone Neoplasms; Etidronic Acid; Half-Life; Humans | 2003 |
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Topics: Aged; Bone Neoplasms; Disease Progression; Dose-Response Relationship, Radiation; Etidronic Acid; Hu | 2003 |
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Topics: Aged; Aged, 80 and over; Blood Cell Count; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged | 2003 |
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; | 2005 |
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Etidronic Acid; Humans; | 2006 |
[186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ma | 2006 |
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Et | 2007 |
Tumor dosimetry on SPECT (186)Re-HEDP scans: variations in the results from the reconstruction methods used.
Topics: Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Male; Prostatic Neopl | 2007 |
Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Bone Density Conservation Agents; Etidroni | 2007 |
Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Palliative Care; Prost | 1994 |
Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Hum | 1996 |
[Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Male; Neoplasm Met | 1996 |
Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Pain Measurement; Palliative Care; Prostatic Neoplasms | 1996 |
Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pa | 1997 |
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Topics: Androgens; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Kidney; Ma | 1999 |
Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP?
Topics: Aged; Blood Platelets; Bone and Bones; Bone Marrow; Bone Marrow Neoplasms; Diphosphonates; Etidronic | 1999 |
Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ma | 2000 |
Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.
Topics: Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Male; Pain Measuremen | 2000 |
[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
Topics: Alkaline Phosphatase; Analgesics; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; | 2000 |
Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid | 2000 |
Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle | 2000 |
[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Leukocyte Count; Male; Middle Aged | 2000 |
Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Pain, Intractable; Palliativ | 2001 |
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
Topics: Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Etidronic Acid; Filg | 2002 |
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances; | 1992 |
Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Topics: Aged; Bone Neoplasms; Double-Blind Method; Etidronic Acid; Female; Humans; Male; Organometallic Comp | 1991 |
Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study.
Topics: Bone Neoplasms; Carcinoma; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Humans; Ma | 1989 |
51 other studies available for etidronate and Prostatic Neoplasms
| Article | Year |
|---|---|
A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; | 2020 |
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
Topics: Bone Neoplasms; Clinical Trials, Phase II as Topic; Etidronic Acid; Humans; Male; Organometallic Com | 2018 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
Topics: Animals; Bone Neoplasms; Etidronic Acid; Feasibility Studies; Humans; Male; Mice; Organometallic Com | 2014 |
Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Chemotherapy, Adjuvant; | 2017 |
Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; | 2009 |
Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density Conservation Agents; Bone Resorption; Et | 2009 |
Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
Topics: Animals; Autoradiography; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; | 2009 |
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidro | 2009 |
Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ka | 2011 |
Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
Topics: Aged; Bone Neoplasms; Drug Resistance, Neoplasm; Etidronic Acid; Follow-Up Studies; Hormones; Humans | 2011 |
Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
Topics: Bone Neoplasms; Drug Resistance, Neoplasm; Etidronic Acid; Hormones; Humans; Male; Organometallic Co | 2012 |
Radionuclide therapy of painful bone metastases--a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Pain; Palliative Care; Prostatic N | 2013 |
The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer.
Topics: Bone and Bones; Bone Neoplasms; Etidronic Acid; Humans; Image Processing, Computer-Assisted; Male; N | 2005 |
Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
Topics: Aged; Bone Neoplasms; Etidronic Acid; Hemoglobins; Humans; Male; Organometallic Compounds; Pain; Pre | 2006 |
[Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy].
Topics: Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fracture | 2008 |
Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Dipho | 2008 |
Myocardial uptake. An unexpected finding in an oncology follow-up.
Topics: Aged; Carcinoma; Coronary Disease; Diphosphonates; Etidronic Acid; Follow-Up Studies; Heart; Heart F | 1983 |
The bone scan as a tumour marker in prostatic carcinoma.
Topics: Bone and Bones; Diphosphates; Diphosphonates; Etidronic Acid; Humans; Male; Organotechnetium Compoun | 1982 |
Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Huma | 1994 |
Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
Topics: Aged; Bone Marrow; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Ma | 1996 |
Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
Topics: Bone Neoplasms; Cranial Nerve Diseases; Etidronic Acid; Glossopharyngeal Nerve; Humans; Hypoglossal | 1996 |
Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model.
Topics: Animals; Etidronic Acid; Lumbar Vertebrae; Male; Prostatic Neoplasms; Radioisotopes; Rats; Rhenium; | 1997 |
Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
Topics: Adult; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ki | 1997 |
[Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Male; Middle Aged; | 1997 |
Rhenium-188(Sn)HEDP for treatment of osseous metastases.
Topics: Aged; Animals; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; | 1998 |
[Advanced prostate carcinoma: systemic radionuclide therapy of bone metastasis with rhenium-168-hydroxyethylidine diphosphonate].
Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Pain Measurement; Palliative Care; Prostatic Neoplasms | 1998 |
The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Antineoplastic A | 1998 |
Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells.
Topics: Animals; Cisplatin; Combined Modality Therapy; Drug Screening Assays, Antitumor; Etidronic Acid; Mal | 1999 |
Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma.
Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Prostatic Neoplasms; Radioisotopes; Radionuclide | 1999 |
Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Org | 2000 |
Advances in our understanding of the treatment of painful bone metastasis.
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pa | 2000 |
[Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Palliative Care; Prost | 1999 |
Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lu | 2000 |
Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Pain; Palliativ | 2000 |
A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Humans; Injections, Intravenous; Male; Midd | 2001 |
A clinical comparison of 2 h and 4 h bone scans obtained with 99Tc H.E.D.P.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Ne | 1978 |
[32P] diphosphonate dose determination in patients with bone metastases from prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis | 1978 |
Absent kidney sign associated with symmetrical and uniformly increased uptake of radiopharmaceutical by the skeleton.
Topics: Adolescent; Adult; Aged; Bone and Bones; Child; Chronic Kidney Disease-Mineral and Bone Disorder; Et | 1977 |
Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumors.
Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lung | 1975 |
Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans.
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lung Neoplasms; Male; Neoplasm Met | 1975 |
Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Pain, | 1992 |
Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Half-Life; Humans; Male; Middle Aged | 1992 |
Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Estrogens; Etidronic Acid; Humans; Male; Organometallic Compou | 1990 |
Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3.
Topics: Animals; Bone Neoplasms; Calcium; Cell Line; Disease Models, Animal; Etidronic Acid; Injections, Sub | 1991 |
Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice.
Topics: Adenocarcinoma; Alendronate; Animals; Diphosphonates; Etidronic Acid; Humans; Male; Mice; Mice, Nude | 1990 |
Treatment of painful prostatic bone metastases with oral etidronate disodium.
Topics: Administration, Oral; Bone Neoplasms; Etidronic Acid; Humans; Male; Orchiectomy; Pain Measurement; P | 1988 |
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.
Topics: Aged; Biopsy; Bone Neoplasms; Bone Resorption; Calcitonin; Carcinoma; Etidronic Acid; Humans; Ilium; | 1987 |
False-negative bone imaging due to etidronate disodium therapy.
Topics: Aged; Bone Neoplasms; Etidronic Acid; False Negative Reactions; Humans; Male; Prostatic Neoplasms; R | 1988 |
[Effects of etidronate disodium (EHDP) on urogenital malignancies with bone metastasis: a multicentered collaborative evaluation].
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Drug Evaluat | 1988 |
Establishment of a model to evaluate inhibition of bone resorption induced by human prostate cancer cells in nude mice.
Topics: Adenocarcinoma; Animals; Bone Neoplasms; Cell Line; Etidronic Acid; Male; Mice; Neoplasm Invasivenes | 1988 |